Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Affect Long-term Outcome of Patients With Peritoneal Metastases From Colorectal Cancer
Authors:
- D. BarattiDBD. Baratti
- S. KusamuraSKS. Kusamura
- D. IuscoDID. Iusco
- S. BonomiSBS. Bonomi
- A. GrassiAGA. Grassi
- S. VirzìSVS. Virzì
- E. LeoELE. Leo
- M. DeracoMDM. Deraco
- 1 July 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 57 (7) , 858-868
Abstract
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is an effective but potentially morbid treatment for colorectal cancer peritoneal metastases. The impact of treatment-related morbidity on long-term survival has been reported in various malignancies, but it has never been assessed in this clinical setting. The aim of this study was to assess the impact of major postoperative complications on oncological outcomes after cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. Two prospective databases were reviewed. Major complications were defined as grade 3 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. The extent of peritoneal involvement was scored by the use of the Peritoneal Cancer Index. This study was conducted in 2 high-volume peritoneal malignancy management centers. One hundred one consecutive patients with peritoneal metastases potentially amenable to macroscopically complete cytoreduction were selected. Peritonectomy procedures and multivisceral resections were used to remove all macroscopic tumor, and mitomycin-C plus cisplatin-based hyperthermic intraperitoneal chemotherapy was used to control microscopic residual disease. The primary outcomes measured were overall and disease-specific survival. Mortality and major morbidity were 3.0%, and 23.8%. Median follow-up was 44.9 months (95% CI, 24.1-65.7). Five-year disease-specific survival was 14.3% for patients who experienced major complications and 52.3% for those who did not (p = 0.001). Five-year overall survival was 11.7% for patients who experienced major complications, and 58.8% for those who did not (p = 0.003). At multivariate analysis, major morbidity correlated to both worse overall and disease-specific survival, along with a Peritoneal Cancer Index >19, and suboptimal cytoreduction. Poor performance status correlated only to worse disease-specific survival, and liver metastases correlated to worse overall survival. Longer operative time (OR, 4.1; 95% CI, 1.3-12.6; p = 0.01) and Peritoneal Cancer Index >19 (OR, 2.6; 95% CI, 1.1-6.0; p = 0.02) were independent risk factors for major morbidity. This study is limited by its observational design. The prevention of major complications, by refining surgical technique and patient selection, is crucial because it affects oncologic outcome.Keywords
This publication has 37 references indexed in Scilit:
- Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 2012
- Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841Journal of Clinical Oncology, 2012
- Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter StudyAnnals of Surgical Oncology, 2011
- Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based studyInternational Journal of Cancer, 2010
- Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal OriginJournal of Clinical Oncology, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Peritoneal Carcinomatosis of Colorectal OriginAnnals of Surgery, 2006
- Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary studyBritish Journal of Cancer, 2004
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 2002